Picture of BioCryst Pharmaceuticals logo

BCRX — BioCryst Pharmaceuticals Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMid CapMomentum Trap

Momentum

Relative Strength (%)
1m+9.54%
3m-0.79%
6m-18.77%
1yr+34.89%
Volume Change (%)
10d/3m+127.11%
Price vs... (%)
52w High-21.16%
50d MA+13.11%
200d MA+2.22%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-136.17%
Return on Equityn/a
Operating Margin-157.82%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Latest News & Insights for BCRX

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202131st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2021 / 2022

Blurred out image of BioCryst Pharmaceuticals EPS forecast chart

Profile Summary

BioCryst Pharmaceuticals, Inc. (BioCryst) is a commercial-stage biotechnology company that discovers small-molecule medicines. The Company focus on oral treatments for rare diseases in which unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease. ORLADEYO (berotralstat) is an oral, once-daily therapy that is approved in the United States, the European Union, Japan, and the United Kingdom for the prevention of hereditary angioedema (HAE) attacks in adults and pediatric patients 12 years and older. BioCryst has several ongoing development programs, including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases; BCX9250, an activin receptor-like kinase-2 (ALK-2) inhibitor for the treatment of fibrodysplasia ossificans progressiva, and Galidesivir, an antiviral drug for Marburg virus disease and Yellow Fever. RAPIVAB (peramivir injection) is a viral neuraminidase inhibitor for the treatment of influenza.

Directors

Last Annual
December 31st, 2020
Last Interim
September 30th, 2021
Incorporated
November 15th, 1991
Public Since
March 4th, 1994
No. of Shareholders
167
No. of Employees
246
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
us flag iconNASDAQ Global Select Market
Shares in Issue
179,791,000

BCRX Share Price Performance

Latest News for BCRX

Upcoming Events for BCRX

Q4 2021 BioCryst Pharmaceuticals Inc Earnings Release

Q1 2022 BioCryst Pharmaceuticals Inc Earnings Release

BioCryst Pharmaceuticals Inc Annual Shareholders Meeting

Similar to BCRX

2Seventy Bio

us flag iconNASDAQ Global Select Market

Picture of 4D Molecular Therapeutics logo

4D Molecular Therapeutics

us flag iconNASDAQ Global Select Market

Picture of AbCellera Biologics logo

AbCellera Biologics

us flag iconNASDAQ Global Select Market

AbSci

us flag iconNASDAQ Global Select Market

Picture of ACADIA Pharmaceuticals logo

ACADIA Pharmaceuticals

us flag iconNASDAQ Global Select Market

FAQ

Or unlock with your email

Or unlock with your email